NASDAQ:TMDX - TransMedics Group Stock Price, Forecast & News

TransMedics Group's stock was trading at $13.62 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TMDX stock has decreased by 13.7% and is now trading at $11.76. View which stocks have been mosted impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for TransMedics Group.

TransMedics Group is scheduled to release its next quarterly earnings announcement on Wednesday, June 10th 2020. View our earnings forecast for TransMedics Group.

TransMedics Group Inc (NASDAQ:TMDX) issued its earnings results on Monday, March, 2nd. The company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.39) by $0.04. The company earned $6.06 million during the quarter, compared to analyst estimates of $6.51 million. View TransMedics Group's earnings history.

TransMedics Group updated its FY 2020 After-Hours earnings guidance on Monday, March, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $40-43 million, compared to the consensus revenue estimate of $46.81 million.

4 brokers have issued 12-month price objectives for TransMedics Group's shares. Their forecasts range from $16.00 to $37.00. On average, they expect TransMedics Group's stock price to reach $28.75 in the next year. This suggests a possible upside of 144.5% from the stock's current price. View analysts' price targets for TransMedics Group.

Media coverage about TMDX stock has been trending somewhat positive recently, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. TransMedics Group earned a coverage optimism score of 1.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View the latest news aboutTransMedics Group.

TransMedics Group saw a decline in short interest in February. As of February 14th, there was short interest totaling 1,420,000 shares, a decline of 10.1% from the January 30th total of 1,580,000 shares. Based on an average trading volume of 197,600 shares, the days-to-cover ratio is presently 7.2 days. Approximately 11.5% of the company's shares are short sold. View TransMedics Group's Current Options Chain.

Some companies that are related to TransMedics Group include Natus Medical (NTUS), InMode (INMD), AxoGen (AXGN), Viewray (VRAY), Zynex (ZYXI), Semler Scientific (SMLR), BioLife Solutions (BLFS), Cutera (CUTR), Stereotaxis (STXS), Rockwell Medical (RMTI), BioSig Technologies (BSGM), Soleno Therapeutics (SLNO), Fonar (FONR), Edap Tms (EDAP) and Fc Global Realty (FCRE).

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Gilead Sciences (GILD), Roku (ROKU), AbbVie (ABBV), AT&T (T), Advanced Micro Devices (AMD), Etsy (ETSY), NVIDIA (NVDA), Walt Disney (DIS), IBM (IBM) and Exxon Mobil (XOM).

(TMDX) raised $75 million in an initial public offering on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

TransMedics Group's stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Credit Suisse AG (5.35%), Sandhill Capital Partners LLC (3.48%), Emerald Advisers LLC (2.13%), Emerald Mutual Fund Advisers Trust (2.03%) and Roubaix Capital LLC (1.25%). Company insiders that own TransMedics Group stock include David Weill, Edwin M Kania Jr and Tamer I Khayal. View institutional ownership trends for TransMedics Group.

TMDX stock was acquired by a variety of institutional investors in the last quarter, including Credit Suisse AG, Emerald Advisers LLC, Sandhill Capital Partners LLC, Emerald Mutual Fund Advisers Trust, State Street Corp, Roubaix Capital LLC, Geode Capital Management LLC, and Oregon Public Employees Retirement Fund. Company insiders that have bought TransMedics Group stock in the last two years include David Weill, and Edwin M Kania Jr. View insider buying and selling activity for TransMedics Group.

Shares of TMDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TMDX stock can currently be purchased for approximately $11.76.

TransMedics Group has a market capitalization of $249.55 million and generates $23.60 million in revenue each year. The company earns $-33,550,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis.  View additional information about TransMedics Group.

The official website for TransMedics Group is http://www.transmedics.com/.

TransMedics Group's mailing address is 200 MINUTEMAN ROAD, ANDOVER MA, 01810. The company can be reached via phone at 978-552-0900 or via email at [email protected]